According to filings with the U.S. Securities and Exchange Commission, Alpha-9 Theranostics is raising $75,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Hirsch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alpha-9 Theranostics
Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

To learn more about Alpha-9 Theranostics, visit http://www.alpha9tx.com/

Contact:
David Hirsch, Chief Executive Officer
778-231-2500

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved.